ARTEMIS clinical trial offers triple-negative patients...
Triple-negative breast cancer (TNBC) makes up 15 to 20 percent of breast cancer diagnoses. The condition often is considered a single...
Possible side effects of immunotherapy — and how to handle...
Over the past decade, immune checkpoint inhibitors have shown success in treating several types of cancer, including melanoma,...
Biomarker predicts response to pancreatic cancer therapy
MD Anderson researchers have discovered that a protein called angiogenin (ANG) serves as a potential biomarker useful for stratifying...
Potential biomarker linked to better outcomes in acute myeloid...
Somatic mutations in certain genes may function as a molecular minimal residual disease marker for acute myeloid leukemia (AML),...
